Striatal dopamine neurons

Striatal dopamine neurons primarily refer to the dopaminergic cell population originating in the substantia nigra pars compacta (SNc) that projects to the striatum via the nigrostriatal pathway (StatPearls, Parkinson Disease). These neurons are fundamental to the basal ganglia's role in regulating voluntary motor control and reward-motivated behavior through the release of dopamine (PubMed, PMC4379295). The progressive degeneration of these neurons is the definitive pathological feature of Parkinson's disease, resulting in motor deficits such as bradykinesia and rigidity (NIH, NINDS). In psychiatric contexts, such as schizophrenia, the overactivity of dopaminergic signaling within the striatum is a primary focus of antipsychotic treatment (PubMed, PMC2894665). Because this term describes a cellular population rather than a specific protein, it is technically an 'incorrect' molecular target; however, it serves as the physiological site for various drug targets including the dopamine transporter (DAT), dopamine receptors (D1-D5), and monoamine oxidase B.

Other names

Nigrostriatal dopaminergic neuronsDopaminergic terminals in the striatumMesostriatal dopamine neuronsStriatal DA neurons

Therapeutic strategies involve the restoration of dopamine levels (precursor replacement), inhibition of dopamine metabolism (MAO-B or COMT inhibitors), or modulation of postsynaptic dopamine receptors (agonism/antagonism) to compensate for neuronal loss or dysregulation.